JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2949 Linifanib (ABT-869)

Target: VEGFR|PDGFR

Summary: VEGFR/PDGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.75 mg/mL
A2174 Lenvatinib (E7080)

Target: VEGFR|PDGFR|RET

Summary: VEGFR inhibitor

≥21.35 mg/mL
A8370 Axitinib (AG 013736)
1 Citation

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR1/ c-Kit inhibitor

insoluble in H2O; ≥19.3 mg/mL
A8550 Telatinib (BAY 57-9352)

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR-2/-3,PDGFR-β and c-Kit inhibitor

insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL
B2173 CP-673451

Target: PDGFR

Summary: PDGFRα/β inhibitor,potent and selective
B5953 Dovitinib (TKI258) Lactate

Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).

insoluble in EtOH; ≥10.62 mg/mL
A3022 Pazopanib (GW-786034)

Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
A3750 Regorafenib hydrochloride

Target: Raf|VEGFR|PDGFR|c-Kit|c-RET

Summary: Tyrosine kinase inhibitor

≥25.95 mg/mL